Evidence map›Paper›PMID 39078624›Full record

ArticleInteractive journal of medical research2024

Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study.

Hideaki L Tanaka, Judy R Rees, Ziyin Zhang, Judy A Ptak, Pamela M Hannigan, Elaine M Silverman, Janet L Peacock, Jay C Buckey, Multicenter Registry for Hyperbaric Oxygen Treatment Consortium

Registry-linked trialAbstract read
In one paragraph

Article in Interactive journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240649 (Emerging Indications for Hyperbaric Oxygen Treatment), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07240649 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Emerging Indications for Hyperbaric Oxygen Treatment

TypeinterventionalSponsorJay C. Buckey Jr.Ran2026 to 2035Enrolled100ConditionsPost-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, CalciphylaxisArmsHyperbaric oxygen treatment (HBOT), 100% Oxygen
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hideaki L TanakaDivision of Undersea and Hyperbaric Medicine, Department of Emergency Medicine, University of California at San Diego, San Diego, CA, United States.ORCID 0000-0002-1340-3891
Judy R ReesGeisel School of Medicine, Dartmouth College, Lebanon, NH, United States.ORCID 0000-0002-8232-1056
Ziyin ZhangGeisel School of Medicine, Dartmouth College, Lebanon, NH, United States.ORCID 0009-0009-8980-6302
Judy A PtakDartmouth-Hitchcock Medical Center, Lebanon, NH, United States.ORCID 0000-0002-5379-5199
Pamela M HanniganDartmouth-Hitchcock Medical Center, Lebanon, NH, United States.ORCID 0000-0003-1536-7932
Elaine M SilvermanDartmouth-Hitchcock Medical Center, Lebanon, NH, United States.ORCID 0009-0003-4998-2500
Janet L PeacockGeisel School of Medicine, Dartmouth College, Lebanon, NH, United States.ORCID 0000-0002-0310-2518
Jay C BuckeyGeisel School of Medicine, Dartmouth College, Lebanon, NH, United States.ORCID 0000-0003-4591-4431
Multicenter Registry for Hyperbaric Oxygen Treatment Consortiumsee Acknowledgments, .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperbaric oxygen (HBO

objectiveAlthough hyperbaric medicine has established indications, new ones continue to emerge. One objective of this registry study was to identify cases where HBO

methodsThis descriptive study used data from a web-based, multicenter, international registry of patients treated with HBO

resultsOut of 9726 patient entries, 378 (3.89%) individuals were treated for 45 emerging indications. Post-COVID-19 condition (PCC; also known as postacute sequelae of COVID-19; 149/378, 39.4%), ulcerative colitis (47/378, 12.4%), and Crohn disease (40/378, 10.6%) accounted for 62.4% (n=236) of the total cases. Calciphylaxis (20/378, 5.3%), frostbite (18/378, 4.8%), and peripheral vascular disease-related wounds (12/378, 3.2%) accounted for a further 13.2% (n=50). Patients with PCC reported significant improvement on the Neurobehavioral Symptom Inventory (NSI score: pretreatment=30.6; posttreatment=14.4; P<.001). Patients with Crohn disease reported significantly improved quality of life (EQ-5D score: pretreatment=53.8; posttreatment=68.8), and 5 (13%) reported closing a fistula. Patients with ulcerative colitis and complete pre- and post-HBO

conclusionsHBO INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/18857.

Indexed as

calciphylaxisfacial fillerfrostbitehyperbaric oxygenhypospadiasinfected implanted hardwareinflammatory bowel diseasePASCPCCpostacute sequelae of COVID-19post–COVID-19 conditionpyoderma gangrenosum

Identifiers

PMID39078624
PMCPMC11372337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.